Abstract 617P
Background
Ewing sarcoma is a neoplasm of neuroectodermal origin arising from bone or soft tissue. The annual incidence of Ewing sarcoma in children is 2.93 per 1,000,000. Acute myeloid leukaemia (AML) is one of the most common malignancies as a complication of primary cancer therapy. There are very few studies reported the association of Ewing sarcoma with AML. So, our aim is to quantify the risk of developing AML in Ewing sarcoma patients and provide updated evidence to the literature.
Methods
We extracted the data from the surveillance, Epidemiology and End Results (SEER) statistical analysis software package (SEER*Stat, version 8.4.1.2). We used the MP-SIR session to identify patients who had ewing sarcoma as a first primary tumor, then diagnosed with acute myeloid leukaemia as a second primary malignancy between 2000 and 2020. We assessed the SIR as Observed/Expected(O/E) and Excess Absolute Risk (EAR) per 10,000 with a 95% Confidence Interval (CI) and statistical significance at P<0.05.
Results
A total of 2631 patients had a median follow-up of 120+ months. Patient with Ewing sarcoma had an increased risk to develop AML with O/E of 145.98 (95% CI:101.68 -203.03, P<0.05, EAR= 21.79). The total cohort of patients had a PC of 32.7, APC of 1.3 (95% CI: 0.6 -2.0; P<0.05. Female patients had a PC of 46.5, APC of 1.7 (95% CI: 0.5 -2.9; P<0.05). about 35 patients developed acute non lymphocytic leukaemia (ANLL) with O/E 130.92 (95% [CI] 91.19 -182.08; P<0.05, EAR 21.77).
Conclusions
Ewing sarcoma is a very rare tumor that it is hard to assess the risk of multiple primary malignancies associated with it. In this study we found patients who developed a primary Ewing sarcoma had significantly high risk of developing Acute myeloid leukemia especially in the first year after diagnosis, so we recommend to start screening for AML once Ewing sarcoma is diagnosed for early detection and better management plan.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
16P - Patient and healthcare practitioner preferences in early-stage triple-negative breast cancer treatment: A discrete choice experiment
Presenter: Jiun-I Lai
Session: Poster Display
Resources:
Abstract
17P - Initial outcomes of the ACT Now PRIME CARE for breast cancer: Prevention of Breast canceR (screening/ stage shifting) utilizing Integrated MobilE Clinics and pAtient Reported online Evaluations and Education
Presenter: Herdee Gloriane Luna
Session: Poster Display
Resources:
Abstract
18P - Optimizing premenopausal HR+ HER2–ve eBC management in India: Insights from expert consensus
Presenter: Anitha Ramesh
Session: Poster Display
Resources:
Abstract
19P - Referral patterns among breast cancer patients in county-level hospitals in China
Presenter: Ping Lu
Session: Poster Display
Resources:
Abstract
20P - Real-world treatment of HER2+ and HR+/HER2- early breast cancer in county areas of China
Presenter: Ping Lu
Session: Poster Display
Resources:
Abstract
21P - Duration of breast cancer trials: Analysis of predicted versus actual completion date
Presenter: Daniëlle Verschoor
Session: Poster Display
Resources:
Abstract
22P - Impact of an online Asian genetic risk calculator on risk perception: Cancer-related distress and uptake of genetic counselling among Malaysian breast cancer patients (The ARiCa Study)
Presenter: HEAMANTHAA Padmanabhan
Session: Poster Display
Resources:
Abstract
23P - Consensus statements and expert recommendations for BRCAm breast cancer in the Asia-Pacific region (STREAM-AP)
Presenter: Soo Chin Lee
Session: Poster Display
Resources:
Abstract
24P - Germline genetic testing for hereditary cancer: A retrospective analysis in a single site referral centre in Malaysia
Presenter: Vivian Lee
Session: Poster Display
Resources:
Abstract
25P - Clinical presentations and prognostication of HER2-low breast cancer in Taiwan
Presenter: Bo-Fang Chen
Session: Poster Display
Resources:
Abstract